http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112716918-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fecf68bc2e2d4c0e265e4a8cf3f04f89 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate | 2021-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc62d3836b735f2734387ef500a53be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f43dd7c45a80763f2e6205a4b55d2b72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a715312f181f9fcce063d29fb09eb5e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6669224bedad691438bd7b18ec6d4f22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ae5be0b273d038ab3c8b0167d59712e |
| publicationDate | 2021-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112716918-A |
| titleOfInvention | Ziprasidone hydrochloride oral instant film preparation and preparation method thereof |
| abstract | The invention provides an oral instant film preparation of ziprasidone hydrochloride and a preparation method thereof. In terms of mass percentage, each dosage unit of the oral instant dissolving film comprises: 40.0-50.0w/w% of active drug ziprasidone hydrochloride (calculated by ziprasidone), 15.0-50.0w/w% of water-soluble Film-forming material, 5.0-30.0w/w% of plasticizer, 0.05-0.5w/w% of surfactant and appropriate amount of stabilizer, flavoring agent and sunscreen. The preparation method is as follows: adding the plasticizer, flavoring agent, sunscreen agent, surfactant, and ziprasidone hydrochloride in the prescribed amounts to the pre-prepared aqueous solution of the film-forming material in sequence, stirring evenly, and ultrasonically defoaming and adding to the solution. The film is continuously coated in a continuous coating machine, and then cut after drying to obtain an oral instant film preparation. The oral instant-dissolving film preparation dissolves rapidly on the oral cavity and tongue, and can be taken without water, which solves the problem of poor medication compliance, Tibetan medicine and vomiting of patients during the current clinical use of ziprasidone hydrochloride, and can improve the effectiveness of the drug and improve patient safety. compliance. |
| priorityDate | 2021-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.